HASAG - Asbestos Disease Support

Here for you at this difficult time.

HASAG Asbestos Disease Support understands how important it is to continue supporting people and their families affected by asbestos-related diseases during this pandemic. For the safety of our patients, their families and our team, our coffee mornings are cancelled until further notice. However, we are running monthly Zoom coffee mornings and we have a Virtual Coffee Morning group on Facebook. Please get in touch if you are interested. We are not visiting patients in their homes, instead we are doing telephone or zoom appointments. We are still in the office and available Monday-Friday 9am-5:30pm via telephone or email. Alternatively you can get in touch with us via social media Monday-Sunday and we will get back to you as soon as possible. Please know that HASAG’s support is still here for you.

Team HASAG.

02380 010 015 / 02380 010 016
HASAG - Asbestos Disease Support
  • Home
  • About
    • Who We Are
    • Our Story
    • Asbestos Related Diseases
  • Support
    • Counselling Service
    • Mesothelioma Patient Charter
    • Legal Help
    • Financial Help
    • The Armed Forces Project
    • Benefits
    • Nurses’ Funding
    • Testimonials
    • Events
    • Photo Galleries
    • Fundraising
    • Coffee Mornings – Asbestos Support Groups
    • Downloads & Resources
  • News
  • Shop
    • My account
    • Basket
  • Contact
  • Donate

Cancer drug ‘Keytruda’ hailed as effective against mesothelioma

Jul 17th, 2017

‘Keytruda’ has been making headlines across the world in recent years and has been hailed by many as an effective, new cancer-fighting drug.

Also known by its generic name, ‘Pembrolizumab’, Keytruda is an immunotherapy drug treatment which stimulates the body’s own immune system to fight cancer cells. It was approved for use in England in September 2015 by the National Institute for Health and Care Excellence (NICE).

Originally developed to treat melanoma skin cancer, it has shown encouraging results in cancers that are difficult to treat, such as lung cancer and mesothelioma.

Clinical trials are now underway and Keytruda is being tested as a potential treatment for mesothelioma.  The drug has been effective at blocking the PD-L1 protein found in cancer cells that suppresses the immune system. To put it simply, as one mesothelioma patient taking part in the UK’s Keytruda clinical trial, says: “a (cancerous) tumour has a switch that turns off the immune system but this drug goes in and switches it back on.”

However, it’s important to point out that Keytruda is not a miracle cure for mesothelioma sufferers. The purpose of the treatment is to limit tumour growth and increase remaining life expectancy.  

Keytruda and compensation

In some situations, it may be possible for mesothelioma sufferers who’ve been exposed to asbestos due to the negligence of their former employers to access medical treatment through the compensation process.

This would involve the employers’ insurers covering the cost of the treatment – even if the exposure to asbestos was many years’ ago. If a compensation claim was successful, then it may be possible to include the cost of new drugs, such as Keytruda.

However, like all medications, Keytruda is not suitable for everyone. Each patient needs to be assessed by qualified, experienced medical practitioners to ensure the treatment is appropriate for them.

If it’s decided that Keytruda is a viable clinical option, a specialist asbestos disease solicitor can then pursue the cost of treatment as part of the compensation claim process by securing interim payments.

This can be hugely beneficial, helping mesothelioma patients gain access to potentially effective, ground-breaking treatment that would in other circumstances be beyond them.

Note of caution

It’s vital to remember that Keytruda is an experimental therapy and clinical trials are still only in the very early stages to determine if it is a potentially effective treatment for mesothelioma.

Research into pioneering drugs is set to continue and in the coming few years, it is likely that we will see some major new developments in the treatment of mesothelioma, with other medications, not just Keytruda becoming available.

The challenge for mesothelioma patients and the solicitors representing them is that new drugs have the potential to significantly increase the cost of compensation claims. This may result in defendants’ insurers arguing about the effectiveness of such treatments and questioning whether the costs of the drugs are reasonable recoverable.

Whatever happens, it’s clear that ground-breaking treatments such as Keytruda have given many mesothelioma patients and their families hope – and that is something that in itself is priceless.

Contact Us

If you or a loved one has been diagnosed with an asbestos-related disease, you are not alone. Call us on: 02380 010 016 / 02380 010 015 or use our Contact Form. You can also follow us on Twitter.

  • Fundraising

  • Support

  • Resources

  • Coffee Mornings

  • Contact Us

Share this article

You may also like...

  • Jul 14th, 2017

    Helen's Hike

  • Jul 17th, 2017

    Peter takes on 100 mile bike ride challenge

View All News

Sign-Up to our Newsletter

* indicates required
HASAG - Asbestos Disease Support
  • The June Hancock Mesothelioma Research Fund
  • Mesothelioma Alliance
©HASAG 2021 Charity Reg No. 1122105 Privacy Policy | Pixels & Things